CIK 0001501697
- Non-accelerated filer
- Smaller reporting company
X4 Pharmaceuticals, Inc
Sign in to watch- Ticker
- XFOR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 273181608
- Phone
- +1 857-529-8300
- Business address
- 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134
- Former names
- Arsanis, Inc.
- Open-market buys, last 90 days
- $11,884
- in 1 filing
- Open-market sales, last 90 days
- $33,658
- in 1 filing
Net −$21,775. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-11-20 | Ross Michael Jay Director | Conversion · Series A-2 Convertible Preferred Stock | −690,259 | 0 | ||
| 2017-11-20 | Ross Michael Jay Director | Conversion · Series A-2 Convertible Preferred Stock | −14,587 | 0 | ||
| 2017-11-20 | Ross Michael Jay Director | Conversion · Series B Convertible Preferred Stock | −721,402 | 0 | ||
| 2017-11-20 | Ross Michael Jay Director | Conversion · Series B Convertible Preferred Stock | −15,246 | 0 | ||
| 2017-11-20 | Ross Michael Jay Director | Conversion · Series C Convertible Preferred Stock | −224,665 | 0 | ||
| 2017-11-20 | Ross Michael Jay Director | Conversion · Series C Convertible Preferred Stock | −4,747 | 0 | ||
| 2017-11-20 | Ross Michael Jay Director | Conversion · Series D Convertible Preferred Stock | −692,552 | 0 | ||
| 2017-11-20 | Ross Michael Jay Director | Conversion · Series D Convertible Preferred Stock | −14,635 | 0 | ||
| 2017-11-20 | Ross Michael Jay Director | Conversion · Series D Convertible Preferred Stock | −1,474,348 | 0 | ||
| 2017-11-20 | Ross Michael Jay Director | Conversion · Series D Convertible Preferred Stock | −50,477 | 0 | ||
| 2017-11-20 | Bill & Melinda Gates Foundation 10% owner | Conversion | +722,179 | 722,179 | ||
| 2017-11-20 | Bill & Melinda Gates Foundation 10% owner | Conversion · Series D Convertible Preferred Stock | −2,464,799 | 0 | ||
| 2017-11-15 | MCGUIRE TERRANCE Director | Grant or award · Common Stock (right to buy) | +25,000 | 25,000 | ||
| 2017-11-15 | Ross Michael Jay Director | Grant or award · Common Stock (right to buy) | +25,000 | 25,000 | ||
| 2017-11-15 | SCHULMAN AMY W Director | Grant or award · Common Stock (right to buy) | +25,000 | 25,000 | ||
| 2017-11-15 | Nessi Claudio Director | Grant or award · Common Stock (right to buy) | +25,000 | 25,000 | ||
| 2017-11-15 | MCGIRR DAVID W J Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2017-11-15 | Gerngross Tillman U. Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2017-11-15 | GORDON CARL L Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2017-11-15 | Clark William D Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 |
Page 24 of 25 · 490 trades